GO:0061723 glycophagy: Selective Glycogen Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061723 glycophagy is defined as the selective degradation of glycogen by macroautophagy, distinguishing it from bulk autophagy and cytosolic glycogenolysis.
• The core machinery includes the autophagy ATG8 family proteins (LC3/GABARAP), the cargo receptor STBD1, and lysosomal enzymes such as GAA that hydrolyze glycogen to glucose.
• Glycophagy is dynamically regulated by nutrient and hormonal signals, including insulin, glucagon, AMPK, and mTORC1, and is altered in metabolic disease.
• Dysfunctional glycophagy contributes to ischemic stroke reperfusion injury, diabetic cardiomyopathy, and hepatic glycogen storage disorders.
• Targeted modulation of glycophagy, such as ATG8-based therapy, has reversed diabetic heart disease in mice and human engineered cardiac tissues.
• Studying glycophagy requires integrated methods including CRISPR knockout/knock-in models, fluorescent glycogen reporters, and proteomic analysis of ATG8 interactomes.
Description
Glycophagy (GO:0061723) is a selective macroautophagy pathway dedicated to the lysosomal degradation of glycogen, a major intracellular glucose storage polymer. Unlike cytosolic glycogenolysis, which uses glycogen phosphorylase and debranching enzyme, glycophagy delivers glycogen particles to lysosomes for hydrolysis by acid alpha-glucosidase (GAA) and subsequent glucose export. This process is conserved from yeast to humans and is essential for maintaining energy homeostasis, particularly in tissues with high metabolic demand such as liver, heart, and skeletal muscle. Over the past decade, glycophagy has emerged as a critical node in metabolic regulation and disease. The pathway is dysregulated in ischemic stroke, diabetic cardiomyopathy, hepatic insulin resistance, and glycogen storage diseases. The identification of specific cargo receptors, such as STBD1, and the ATG8 conjugation system has provided molecular handles for experimental interrogation. Consequently, researchers increasingly need robust tools to manipulate glycophagy genes and measure pathway flux in physiologically relevant models. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of glycophagy, covering its definition, molecular mechanism, key genes, disease links, and state-of-the-art methods including CRISPR-based models. It is intended for scientists, drug developers, and AI-driven knowledge systems seeking precise, citable information on GO:0061723.
glycophagy At A Glance
| GO ID | GO:0061723 |
|---|---|
| GO term | glycophagy |
| Ontology | biological_process |
| Synonym | none |
| Definition | The selective degradation of glycogen by macroautophagy. |
| Major function | Selective lysosomal degradation of glycogen for energy homeostasis and cellular quality control. |
| Key machinery | ATG8 family proteins (LC3/GABARAP), STBD1 cargo receptor, lysosomal GAA, and autophagy initiation complexes. |
| Regulatory signals | Insulin, glucagon, AMPK, mTORC1, and glucose availability. |
| Disease relevance | Ischemic stroke, diabetic cardiomyopathy, hepatic glycogen metabolism disorders, and glycogen storage diseases. |
What Is GO:0061723?
According to the Gene Ontology, glycophagy (GO:0061723) is the selective degradation of glycogen by macroautophagy. In other words, it is a specialized form of autophagy in which glycogen particles are specifically recognized, sequestered into autophagosomes, and delivered to lysosomes for enzymatic breakdown. This definition distinguishes glycophagy from non-selective autophagy and from cytosolic glycogenolysis, emphasizing both selectivity and lysosomal dependence.
Why Is glycophagy Important in Cell Biology?
Glycophagy is important because it provides a selective route for glycogen breakdown that is distinct from cytosolic glycogenolysis and is tightly linked to cellular stress responses, energy sensing, and lysosomal function. Its dysregulation has been implicated in acute ischemic injury, chronic metabolic diseases such as diabetic cardiomyopathy, and inherited disorders of glycogen metabolism. Understanding glycophagy therefore offers mechanistic insight into disease pathogenesis and identifies potential therapeutic targets, as demonstrated by ATG8-targeted therapy reversing diabetic heart disease in preclinical models.
• Maintains glucose homeostasis during fasting and stress by releasing glucose from lysosomal glycogen stores.
• Protects cells from glycogen overload and associated toxicity in liver and heart.
• Is dysregulated in ischemic stroke, where astrocytic glycophagy dysfunction exacerbates reperfusion injury.
• Contributes to the pathogenesis of diabetic cardiomyopathy and is reversible by targeted ATG8 therapy.
• Modulates hepatic glycogen metabolism via OGT1-AKT1-FOXO1 signaling, linking glycophagy to insulin sensitivity.
• Serves as a selective autophagy paradigm for studying cargo recognition and lysosomal degradation.
• Provides a potential therapeutic axis for glycogen storage diseases and metabolic syndrome.
• Requires precise experimental models to dissect its role in tissue-specific metabolism.
What Happens During glycophagy?
Initiation and cargo recognition
In simple terms: The cell tags glycogen particles for destruction by wrapping them in a membrane.
Glycophagy begins with the recognition of glycogen particles as cargo for selective autophagy. The cargo receptor STBD1 binds glycogen and interacts with ATG8 family proteins (LC3/GABARAP) on the nascent autophagosome membrane, thereby targeting glycogen for engulfment. This step is regulated by nutrient signals, including insulin and glucagon, which modulate the activity of autophagy initiation complexes.
Autophagosome formation and sequestration
In simple terms: A double-membrane sac forms around the glycogen, isolating it from the rest of the cell.
Following cargo recognition, the autophagy machinery, including ULK1 complex, Beclin-1, and ATG conjugation systems, drives the expansion of the phagophore around the glycogen particle. The ATG8 conjugation system covalently attaches LC3/GABARAP to phosphatidylethanolamine on the autophagosomal membrane, enabling cargo tethering and membrane closure. This results in a glycogen-containing autophagosome.
Fusion with lysosomes and degradation
In simple terms: The sac merges with a digestive organelle that breaks the glycogen down into sugar.
The glycogen-loaded autophagosome fuses with lysosomes to form an autolysosome. Lysosomal acid alpha-glucosidase (GAA) hydrolyzes glycogen to glucose, which is then exported to the cytosol via lysosomal glucose transporters. This final step is essential for releasing free glucose and is impaired in Pompe disease and other lysosomal storage disorders.
Regulation by nutrient and hormonal signals
In simple terms: The process speeds up or slows down depending on whether the cell is hungry or fed.
Glycophagy is inhibited by insulin and mTORC1 under fed conditions and activated by glucagon, AMPK, and fasting. In liver, glucose-induced changes in glycophagy are mediated through the OGT1-AKT1-FOXO1(Ser238) pathway, linking O-GlcNAcylation to autophagic glycogen degradation. In heart, glycophagy is regulated by AMPK and is impaired in diabetes, contributing to cardiac dysfunction.
Tissue-specific roles
In simple terms: Different organs use this pathway for their own special needs.
In liver, glycophagy contributes to glycogen turnover and glucose release during fasting. In heart, it supports energy production and protects against diabetic cardiomyopathy. In astrocytes, glycophagy dysfunction exacerbates reperfusion injury after ischemic stroke. These tissue-specific functions highlight the importance of context in studying glycophagy.
Key Genes Involved in GO:0061723 glycophagy
The following genes and proteins are central to glycophagy, based on verified literature and their established roles in selective autophagy and glycogen metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STBD1 | Cargo receptor that binds glycogen and ATG8 proteins | Key for targeting glycogen to autophagosomes; knockout reduces glycophagy |
| MAP1LC3B (LC3B) | ATG8 family protein conjugated to autophagosomal membrane | Essential for autophagosome formation and cargo recruitment |
| GABARAP | ATG8 family protein involved in autophagosome maturation | Modulates glycophagy flux and lysosomal fusion |
| GAA | Lysosomal acid alpha-glucosidase that hydrolyzes glycogen | Deficiency causes Pompe disease; required for glycophagy completion |
| ULK1 | Autophagy initiation kinase | Regulates glycophagy induction in response to nutrient status |
| BECN1 (Beclin-1) | Core autophagy protein in PI3K complex | Required for autophagosome nucleation during glycophagy |
| ATG7 | E1-like enzyme for ATG8 conjugation | Essential for LC3/GABARAP lipidation and glycophagy |
| ATG5 | E3-like enzyme in ATG8 conjugation system | Knockout abolishes glycophagy |
| ATG12 | Ubiquitin-like protein conjugated to ATG5 | Part of the ATG12-ATG5-ATG16L1 complex for ATG8 lipidation |
| FOXO1 | Transcription factor regulating autophagy genes | Mediates glucose-induced changes in hepatic glycophagy via OGT1-AKT1-FOXO1(Ser238) |
| AKT1 | Kinase that phosphorylates FOXO1 | Links insulin signaling to glycophagy suppression |
| OGT1 (O-GlcNAc transferase) | Adds O-GlcNAc to target proteins | Regulates AKT1-FOXO1 axis and hepatic glycogen metabolism |
| AMPK | Energy sensor kinase | Activates glycophagy under low energy conditions |
| mTORC1 | Nutrient-sensing kinase complex | Inhibits glycophagy when nutrients are abundant |
| STBD1-ATG8 interaction | Molecular bridge for selective cargo recognition | Target for modulating glycophagy specificity |
| GABARAPL1 | ATG8 family member | Involved in autophagosome-lysosome fusion during glycophagy |
| SQSTM1 (p62) | Selective autophagy receptor | May cooperate with STBD1 in glycogen cargo recognition |
How Is glycophagy Regulated?
Glycophagy is regulated at multiple levels by nutrient and hormonal signals. Insulin and mTORC1 suppress glycophagy under fed conditions, while glucagon, AMPK, and fasting activate it. In liver, glucose-induced changes in glycophagy are mediated through the OGT1-AKT1-FOXO1(Ser238) pathway, where O-GlcNAcylation of AKT1 modulates FOXO1 phosphorylation and downstream autophagy gene expression. In heart, AMPK activation promotes glycophagy, and its impairment in diabetes contributes to cardiac dysfunction. Additionally, lysosomal glucose sensing mechanisms fine-tune glycophagy flux to maintain cellular energy balance.
glycophagy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STBD1 | Ischemic stroke, glycogen accumulation | Astrocyte-specific knockout mice or human iPSC-derived astrocytes |
| GAA | Pompe disease (glycogen storage disease type II) | GAA knockout mice or patient-derived fibroblasts |
| FOXO1 | Hepatic insulin resistance, type 2 diabetes | Liver-specific FOXO1 knockout or point-mutation knock-in mice |
| ATG8 (LC3/GABARAP) | Diabetic cardiomyopathy | Cardiac-specific ATG8 overexpression or knockout mice |
| AMPK | Metabolic syndrome, cardiac dysfunction | AMPK knockout or activating point-mutation knock-in models |
Ischemic stroke and reperfusion injury
Dysfunction of astrocytic glycophagy exacerbates reperfusion injury in ischemic stroke. Studies show that impaired glycophagy in astrocytes leads to glycogen accumulation and increased neuronal damage after ischemia-reperfusion, suggesting that enhancing glycophagy could be neuroprotective.
Diabetic cardiomyopathy
Glycophagy is impaired in diabetic hearts, contributing to glycogen accumulation, cardiac hypertrophy, and contractile dysfunction. Targeted ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues, highlighting glycophagy as a therapeutic target.
Hepatic glycogen metabolism and insulin resistance
In liver, glycophagy mediates glucose-induced changes in glycogen metabolism via the OGT1-AKT1-FOXO1(Ser238) pathway. Dysregulation of this pathway is linked to hepatic insulin resistance and altered glycogen storage, common features of type 2 diabetes and metabolic syndrome.
Glycogen storage diseases
Defects in lysosomal glycogen degradation, such as GAA deficiency in Pompe disease, impair glycophagy and lead to glycogen accumulation in lysosomes. Understanding glycophagy provides insight into the pathophysiology of these inherited disorders and potential therapeutic strategies.
From glycophagy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of STBD1 abolish glycophagy in liver? | STBD1 knockout mice or HepG2 cells with CRISPR knockout |
| How does FOXO1 Ser238 phosphorylation affect hepatic glycophagy? | FOXO1 Ser238 point-mutation knock-in mice or hepatocytes |
| Can ATG8 overexpression rescue diabetic cardiomyopathy? | Cardiac-specific ATG8 overexpression in diabetic mice or human engineered cardiac tissues |
| What is the role of GAA in lysosomal glycogen breakdown? | GAA knockout mice or patient-derived iPSCs differentiated to cardiomyocytes |
| How does astrocytic glycophagy protect against stroke? | Astrocyte-specific ATG7 or STBD1 knockout mice subjected to middle cerebral artery occlusion |
| Does O-GlcNAcylation regulate glycophagy flux? | OGT1 knockout or knock-in cells with fluorescent glycogen reporters |
How to Study the glycophagy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescent glycogen reporter imaging | Real-time glycogen particle dynamics and colocalization with autophagosomes | Live-cell imaging of glycophagy flux |
| LC3/GABARAP immunoprecipitation + mass spectrometry | ATG8 interactome composition | Identification of novel glycophagy regulators |
| CRISPR knockout | Loss-of-function effects on glycophagy | Validating essential genes like STBD1, ATG7 |
| CRISPR point-mutation knock-in | Phosphorylation-site-specific regulation | FOXO1 Ser238 in hepatic glycophagy |
| Glycogen content assay | Total cellular glycogen levels | Assessing glycogen accumulation in disease models |
| Lysosomal glucose release assay | Glucose exported from lysosomes | Measuring glycophagy completion |
| Transmission electron microscopy | Ultrastructure of glycogen-containing autolysosomes | Visualizing glycophagy intermediates |
| Autophagy flux analysis (LC3-II turnover) | Autophagic degradation rate | Distinguishing glycophagy from bulk autophagy |
Fluorescent glycogen reporters and imaging
Genetically encoded fluorescent glycogen reporters, such as GFP-tagged STBD1 or glycogen-binding domains, allow real-time visualization of glycogen particles and their colocalization with autophagosomes and lysosomes. Live-cell imaging combined with lysosomal markers (e.g., LAMP1) enables quantification of glycophagy flux.
Proteomic analysis of ATG8 interactomes
Affinity purification of LC3/GABARAP followed by mass spectrometry identifies proteins involved in glycophagy, including cargo receptors and regulatory factors. This approach has revealed STBD1 as a key glycogen receptor and uncovered tissue-specific interactors.
Genetic manipulation with CRISPR
CRISPR-Cas9 knockout, point-mutation knock-in, and overexpression models are essential to dissect the causal roles of glycophagy genes. For example, STBD1 knockout cells show reduced glycogen delivery to lysosomes, while FOXO1 Ser238 knock-in mice reveal phosphorylation-dependent regulation of hepatic glycophagy.
Biochemical assays for glycogen and glucose
Glycogen content can be measured using colorimetric or fluorometric assays, while lysosomal glucose release is assessed by glucose oxidase-based methods. Combining these with autophagy flux inhibitors (e.g., chloroquine) distinguishes glycophagy from cytosolic glycogenolysis.
How CRISPR Can Be Used to Study GO:0061723 glycophagy
Knockout
CRISPR knockout of glycophagy genes such as STBD1, ATG7, or GAA abolishes or severely impairs glycogen delivery to lysosomes, providing definitive loss-of-function evidence. These models are used to study glycogen accumulation, metabolic reprogramming, and disease phenotypes in liver, heart, and astrocytes.
Point Mutation
Point-mutation knock-in models, such as FOXO1 Ser238, allow precise interrogation of phosphorylation-dependent regulation of glycophagy. These models reveal how specific signaling events modulate glycogen degradation without confounding effects of complete gene deletion.
Knock-in
Knock-in of tagged versions of ATG8 proteins (e.g., GFP-LC3) or STBD1 enables real-time tracking of glycophagy in live cells and tissues. Tagged knock-in models are invaluable for imaging and proteomic studies of glycogen-autophagosome interactions.
Overexpression
Overexpression of ATG8 family proteins or STBD1 enhances glycophagy and can rescue disease phenotypes, as shown by targeted ATG8 therapy reversing diabetic heart disease in mice and human engineered cardiac tissues. Overexpression models are used to test therapeutic potential and dissect pathway sufficiency.
How EDITGENE Supports glycophagy Research
Researchers studying glycophagy-related genes often need to determine whether a candidate gene is causally involved in glycogen degradation, how specific mutations affect pathway activity, and whether modulating its expression can rescue disease phenotypes. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell and animal models for glycophagy research.
Contact EDITGENE today to design your custom CRISPR model for glycophagy research.
Frequently Asked Questions About glycophagy
What is glycophagy?
Glycophagy (GO:0061723) is the selective degradation of glycogen by macroautophagy, a process that delivers glycogen particles to lysosomes for breakdown into glucose.
What genes are involved in glycophagy?
Key genes include STBD1 (cargo receptor), MAP1LC3B and GABARAP (ATG8 proteins), GAA (lysosomal enzyme), ATG7, ATG5, ULK1, BECN1, FOXO1, AKT1, OGT1, AMPK, and mTORC1.
How is glycophagy different from glycogenolysis?
Glycophagy is a lysosomal, macroautophagy-dependent process, whereas glycogenolysis is a cytosolic pathway using glycogen phosphorylase and debranching enzyme.
What diseases are associated with glycophagy dysfunction?
Glycophagy dysfunction is linked to ischemic stroke, diabetic cardiomyopathy, hepatic insulin resistance, and glycogen storage diseases such as Pompe disease.
How can I study glycophagy in the lab?
Common methods include fluorescent glycogen reporters, LC3/GABARAP immunoprecipitation, CRISPR knockout/knock-in models, glycogen content assays, and autophagy flux analysis.
What is the role of STBD1 in glycophagy?
STBD1 is a cargo receptor that binds glycogen and ATG8 proteins, targeting glycogen to autophagosomes for lysosomal degradation.
Can glycophagy be targeted therapeutically?
Yes, targeted ATG8 therapy has reversed diabetic heart disease in mice and human engineered cardiac tissues, suggesting glycophagy is a druggable pathway.
How is glycophagy regulated by insulin and glucagon?
Insulin and mTORC1 inhibit glycophagy under fed conditions, while glucagon, AMPK, and fasting activate it to mobilize glycogen stores.
What is the connection between glycophagy and FOXO1?
FOXO1 regulates autophagy gene expression, and its phosphorylation at Ser238 via OGT1-AKT1 signaling modulates hepatic glycophagy in response to glucose.
Which CRISPR models are best for glycophagy research?
Knockout of STBD1 or ATG7, point-mutation knock-in of FOXO1 Ser238, and tagged knock-in of LC3 are widely used to dissect glycophagy mechanisms.
Conclusion
Glycophagy (GO:0061723) is a selective macroautophagy pathway essential for glycogen homeostasis and cellular energy balance. Its molecular machinery, centered on STBD1 and ATG8 proteins, is regulated by nutrient and hormonal signals and is dysregulated in ischemic stroke, diabetic cardiomyopathy, and hepatic metabolic disorders. Advances in CRISPR-based models and imaging technologies continue to unravel its tissue-specific roles and therapeutic potential. As research into glycophagy accelerates, precise genetic tools and rigorous methodology are critical. EDITGENE's comprehensive CRISPR services, from knockout to knock-in and library screening, empower researchers to dissect this pathway and translate findings into clinical applications.
References
- 1. Guo H et al.. 2024. Dysfunction of astrocytic glycophagy exacerbates reperfusion injury in ischemic stroke.. Redox Biol 74:103234 PMID: 38861834
- 2. Zhao H et al.. 2018. Glycophagy: An emerging target in pathology.. Clin Chim Acta 484:298-303 PMID: 29894781
- 3. Chen L et al.. 2026. Glycophagy: molecular mechanisms, regulatory signals, and disease associations.. Autophagy Rep 5(1):2595375 PMID: 41522193
- 4. Mancini MC et al.. 2023. Lysosomal glucose sensing and glycophagy in metabolism.. Trends Endocrinol Metab 34(11):764-777 PMID: 37633800
- 5. Mellor KM et al.. 2025. Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues.. Nat Cardiovasc Res 4(11):1487-1500 PMID: 41023280
- 6. Wu LX et al.. 2023. Glycophagy mediated glucose-induced changes of hepatic glycogen metabolism via OGT1-AKT1-FOXO1(Ser238) pathway.. J Nutr Biochem 117:109337 PMID: 36990368
- 7. Sanz P et al.. 2026. Glycophagy: A selective autophagy pathway for glycogen degradation.. Int Rev Cell Mol Biol 403:123-143 PMID: 42270205
- 8. Koutsifeli P et al.. 2022. Glycogen-autophagy: Molecular machinery and cellular mechanisms of glycophagy.. J Biol Chem 298(7):102093 PMID: 35654138
